Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection

Clinical Epigenetics

Volumn 8, Issue 1, 2016, Pages

  Su, Yun ^a   Fang, HongBin ^b   Jiang, Feng ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; DNA methylation; Lung cancer; MicroRNA; Sputum

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 21; MICRORNA 210; MICRORNA 31; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; GENETIC MARKER; MICRORNA; MIRN21 MICRORNA, HUMAN; MIRN210 MICRORNA, HUMAN; MIRN31 MICRORNA, HUMAN; PRDM14 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

3OST2 GENE; AGED; ARTICLE; CANCER STAGING; CELL VIABILITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA METHYLATION; EARLY CANCER DIAGNOSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRDM14 GENE; PRIORITY JOURNAL; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; VALIDATION PROCESS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; SPUTUM;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY; SPUTUM; TUMOR SUPPRESSOR PROTEINS;

EID: 84992034940     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-016-0275-5     Document Type: Article

References (46)

1. Cancer facts & figures 2012. American Cancer Society (ACS). Journal of Consumer Health on the Internet. 2012; 16:366–367.
2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
3. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004;4:707–17.
4. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis. Proc Am Thorac Soc. 2012;9:38–42.
5. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3:535–7.
6. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006;66:3338–44.
7. Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl. 2000;35:78–83.
8. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95:11891–6.
9. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002;62:2370–7.
10. Hubers AJ, Heideman DA, Burgers SA, Herder GJ, Sterk PJ, Rhodius RJ, et al. DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. Br J Cancer. 2015;112:1105–13.
11. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
13. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170–6.
14. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010;23:1157–64.
15. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010;127:2870–8.
16. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9:33–40.
17. Xing L, Su J, Guarnera MA, Zhang H, Cai L, Zhou R, et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015;21:484–9.
18. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Baron AE, Hirsch FR, et al. Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn. 2003;5:103–12.
19. Varella-Garcia M, Kittelson J, Schulte AP, Vu KO, Wolf HJ, Zeng C, et al. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect Prev. 2004;28:244–51.
20. Yu L, Shen J, Mannoor K, Guarnera M, Jiang F. Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics. Clin Lung Cancer. 2014;15:372–8. e1.
21. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140:145–50.
22. Anjuman N, Li N, Guarnera M, Stass SA, Jiang F. Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clin Transl Med. 2013;2:15.
23. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA. A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila). 2010;3:1571–8.
24. Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer. 2009;66:58–63.
25. Katz RL, Zaidi TM, Fernandez RL, Zhang J, He W, Acosta C, et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod Pathol. 2008;21:950–60.
26. Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, et al. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer. 2008;114:275–83.
27. Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, et al. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res. 2007;13:482–7.
28. Saccomanno G, Saunders RP, Archer VE, Auerbach O, Kuschner M, Beckler PA. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol. 1965;9:413–23.
29. Hubers AJ, van der Drift MA, Prinsen CF, Witte BI, Wang Y, Shivapurkar N, et al. Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer. 2014;84:127–33.
30. Su J, Liao J, Gao L, Shen J, Guarnera MA, Zhan M, et al. Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis. Oncotarget. 2015;87:128–36.
31. Bohning D. Youden’s index and the likelihood ratio positive in diagnostic testing. Methods Inf Med. 2015;54:382–3.
32. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.
33. Wang S, Hu J, Zhang D, Li J, Fei Q, Sun Y. Prognostic role of microRNA-31 in various cancers: a meta-analysis. Tumour Biol. 2014;35:11639–45.
34. Chang W, Lee CY, Park JH, Park MS, Maeng LS, Yoon CS, et al. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci. 2013;14:69–76.
35. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.
36. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013;42:67–71.
37. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007;26:7283–301.
38. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–9.
39. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120:3163–72.
40. Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, et al. Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem. 1999;274:5185–92.
41. Chen H, Zhang C, Sheng Y, Yao S, Liu Z, Zhang T. Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. Am J Cancer Res. 2015;5:180–90.
42. Hubers AJ, Brinkman P, Boksem RJ, Rhodius RJ, Witte BI, Zwinderman AH, et al. Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. J Clin Pathol. 2014;67:707–11.
43. Katz RL, He W, Khanna A, Fernandez RL, Zaidi TM, Krebs M, et al. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res. 2010;16:3976–87.
44. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, et al. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene. 2006;25:2628–35.
45. Jiang F, Caraway NP, Nebiyou Bekele B, Zhang HZ, Khanna A, Wang H, et al. Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer. Clin Cancer Res. 2005;11:5417–24.
46. Jiang F, Yin Z, Caraway NP, Li R, Katz RL. Genomic profiles in stage I primary non-small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia. 2004;6:623–35.